
    
      Open multicentre study with 4 treatment groups. Two groups will receive the 134612 vaccine
      with Priorix-Tetra either at the same or different visits followed by a second Priorix-Tetra
      vaccination at 84 days.

      Two control groups will receive Priorix-Tetra and Meningitec at different visits followed by
      a second Priorix-Tetra vaccination at 84 days.

      For all subjects, two blood samples will be taken: prior to and 42 days after the first
      vaccination. In a subset (30% of subjects in Groups A en C) from selected study centres:
      additional sample 42 days after second Priorix-Tetra dose.
    
  